TD

Tim Davis

Founder at Source Healthcare

Santa Monica, California

Invests in

Stages:

Locations:

  • Min Investment:

    $100,000.00
  • Max Investment:

    $5,000,000.00
  • Target Investment:

    $1,500,000.00

Education

Work Experience

  • Principal Investigator

    2022

  • Principal Investigator

    2021

2021

  • Founder

    2021

    BluByrd is a project management SaaS to organize your surgical cases. The healthcare system is held together by a tangled web of disjointed data, band-aided by manual processes that fail to move surgeries and patients forward. BluByrd streamlines workflows and data exchange between Clinical Practices, Surgical Facilities, and multiple other stakeholders helping to get surgical cases across the finish line, in record time. A single source of truth for your surgical case workflow. www.blubyrd.com

Source Healthcare

2018

  • Founder

    2018

    Spine and Joint Specialists focused on minimally invasive and regenerative methods of treating acute and chronic musculoskeletal injuries. Client-centric, Digitally Integrated, and Efficient Healthcare

  • Founder

    2019

    Multi-specialty Ambulatory Surgery Center focused on customer service and digital integration. Client-centric, Digitally Integrated, and Efficient Healthcare.

  • Principal Investigator

    2018

    The purpose of this study is to compare the safety and preliminary efficacy of intradiscal injections of two doses of IDCT (Discogenic Cells + Sodium Hyaluronate vehicle) and two controls (saline, Sodium Hyaluronate vehicle) in subjects with chronic low back pain due to Degenerative Disc Disease (DDD) at one lumbar level from L3 to S1.

  • Principal Investigator

    2018

    A randomized, double-blind, placebo-controlled, multi-center, phase 3 study to determine the safety and efficacy of TG-C (Genetically Modified Juvenile Chondrocyte) in subjects with Kellgren and Lawrence Grade 2 or 3 Osteoarthritis of the Knee, Osteoarthritis Research Society International (OARSI) medial joint space narrowing (JSN) Grade 1 or 2 of the knee joint. TG-C is to be administered by a single intra-articular injection to the damaged joint area via ultrasound guidance. Patients will be followed for 24 months for safety and efficacy

  • Principal Investigator

    2016

    This is a prospective, multicenter, randomized, double-blind, placebo-controlled Phase 3 study designed to evaluate the safety and efficacy of Mesoblast's rexlemestrocel-L alone or combined with hyaluronic acid (HA) in subjects with chronic low back pain (> 6 months) associated with moderate radiographic degenerative changes of a disc https://clinicaltrials.gov/ct2/show/NCT02412735?term=mesoblast&rank=1

  • Principal Investigator

    2014

    Nerve Ablation by Cooled Radiofrequency Compared to Corticosteroid Injection for Management of Knee Pain This study is designed to: Determine the effectiveness (primarily measured by pain relief) of Coolief when used to create radiofrequency lesions of the genicular nerves compared to pain relief following corticosteroid injection; and Confirm the safety of Coolief when used to perform radiofrequency lesions of the genicular nerves in subjects to manage knee pain compared to safety of corticosteroid injection Orthopedic Pain Specialists enrolled 32 subjects and was the #1 enrolling site in the country.

  • Physical Medicine and Rehabilitation, Interventional Pain

    2000